EU-X-CT - Cross-Border Access to Clinical Trials Initiative

?? We are excited to announce the launch of a new tool that provides country-specific legal, ethical, and financial information on cross-border access to clinical trials ? ??The tool is aimed at both patients and investigators. ? For patients, it helps understand options when seeking clinical trial participation abroad. ? For investigators, it helps navigate regulations to enroll cross-border participants. The preliminary version launched today covers a first group of EU countries. In the future, we aim to expand coverage to all European countries and keep the tool regularly updated. ?? Join us in raising accessibility to cross-border clinical trials: https://lnkd.in/eiQaYmdd Explore the tool, share your feedback, and help us improve access to clinical trials for all. #ClinicalTrials #CrossBorderAccess #EUHealthcare #EUXCT

??? The Public Consultation for the EU-X-CT draft recommendations is still open—don't miss your chance to contribute! Your insights are crucial in shaping guidelines that enhance access to cross-border clinical trials in Europe. If you haven’t reviewed the recommendations yet, now is the time! ?? Submit your comments here: https://lnkd.in/eG769Jrf ?? Closing date: 31 March 2025, 12 PM CEST? Together, we can help break down barriers and make clinical trials more accessible for all! #ClinicalTrials #CrossBorder #HealthcareInnovation #PublicConsultation #PatientAdvocacy

?? NEW: Denmark and Spain ADDED to Our Country Analysis Tool! ?? Are you a patient or investigator looking to enrol clinical trials? Do you need guidance on financial, legal and ethical conditions and requirements for participation? ?? Our Country Analysis Tool empowers you with the insights you need https://lnkd.in/eiQaYmdd Bringing together expertise from 100+ EU-X-CT members across 30+ countries and multiple stakeholders, the tool identifies key conditions in Europe. For patients with rare or life-impacting diseases, clinical trials abroad can offer a vital chance of life-extending or even life-saving treatments. ?? We continue to add more countries and hope to move closer to a future where cross-border access to clinical trials is a reality. ?? #ClinicalTrials #CrossBorderAccess #RareDiseases #EUXCT

?? We are excited to announce the launch of a new tool that provides country-specific legal, ethical, and financial information on cross-border access to clinical trials ? ??The tool is aimed at both patients and investigators. ? For patients, it helps understand options when seeking clinical trial participation abroad. ? For investigators, it helps navigate regulations to enroll cross-border participants. The preliminary version launched today covers a first group of EU countries. In the future, we aim to expand coverage to all European countries and keep the tool regularly updated. ?? Join us in raising accessibility to cross-border clinical trials: https://lnkd.in/eiQaYmdd Explore the tool, share your feedback, and help us improve access to clinical trials for all. #ClinicalTrials #CrossBorderAccess #EUHealthcare #EUXCT

?? Registrations are open! EU-X-CT Public Stakeholders Conference 2025 – Making Cross-Border Access to Clinical Trials a Reality ? The pan-European EU-X-CT Initiative is dedicated to facilitating cross-border access to clinical trials. By gathering insights on regulatory, ethical, social security, and organizational conditions, we aim to identify challenges, share best practices, and drive meaningful improvements across Europe. This Public Stakeholders Conference is your opportunity to collaborate, exchange insights, and shape the future of cross-border clinical trials. Together, we will review national conditions for patients, clinical investigators, academia, public funders, and industry sponsors. The EU-X-CT gap analysis will guide our discussions to define the most effective European and national strategies for improvement in the near and mid-term future. ? ?? Be part of the conversation and help drive change! ?? Date: Tuesday, June 24, 2025 ?? Time: 09:00 – 17:00 CEST ?? Location: Crowne Plaza Brussels, Belgium (hybrid event) ?? Secure your spot today: https://lnkd.in/eZ9zasW7 ? #EUXCT #ClinicalTrials #HealthcareInnovation #EUHealthcare #CrossBorderTrials #RareDiseases

?? Registrations are open! EU-X-CT Public Stakeholders Conference 2025 – Making Cross-Border Access to Clinical Trials a Reality ? The pan-European EU-X-CT Initiative is dedicated to facilitating cross-border access to clinical trials. By gathering insights on regulatory, ethical, social security, and organizational conditions, we aim to identify challenges, share best practices, and drive meaningful improvements across Europe. This Public Stakeholders Conference is your opportunity to collaborate, exchange insights, and shape the future of cross-border clinical trials. Together, we will review national conditions for patients, clinical investigators, academia, public funders, and industry sponsors. The EU-X-CT gap analysis will guide our discussions to define the most effective European and national strategies for improvement in the near and mid-term future. ? ?? Be part of the conversation and help drive change! ?? Date: Tuesday, June 24, 2025 ?? Time: 09:00 – 17:00 CEST ?? Location: Crowne Plaza Brussels, Belgium (hybrid event) ?? Secure your spot today: https://lnkd.in/eZ9zasW7 ? #EUXCT #ClinicalTrials #HealthcareInnovation #EUHealthcare #CrossBorderTrials #RareDiseases

??Check out new country analysis tool by EU-X-CT - Cross-Border Access to Clinical Trials Initiative alliance?? ? CPE, as a proud?member of the EU-X-CT?alliance,?is excited to share the launch of the Country Analysis Tool, a unique platform offering legal, ethical, and financial information?to support cross-border access to clinical trials. ??The tool is aimed at both patients and investigators. ??For patients, it helps understand options when seeking clinical trial participation abroad. ??For investigators, it helps navigate regulations to enrol cross-border participants. The current version has a limited number of countries?listed but we are aiming at Europe?wide?expansion soon to foster more access to cross-border clinical?trials. ?? Explore it here: https://lnkd.in/eiQaYmdd EFPIA - European Federation of Pharmaceutical Industries and Associations EFGCP - European Forum for Good Clinical Practice ?? Read more about CPE's contribution to EU-X-CT: https://lnkd.in/eK-P9Xhg

?? We are excited to announce the launch of a new tool that provides country-specific legal, ethical, and financial information on cross-border access to clinical trials ? ??The tool is aimed at both patients and investigators. ? For patients, it helps understand options when seeking clinical trial participation abroad. ? For investigators, it helps navigate regulations to enroll cross-border participants. The preliminary version launched today covers a first group of EU countries. In the future, we aim to expand coverage to all European countries and keep the tool regularly updated. ?? Join us in raising accessibility to cross-border clinical trials: https://lnkd.in/eiQaYmdd Explore the tool, share your feedback, and help us improve access to clinical trials for all. #ClinicalTrials #CrossBorderAccess #EUHealthcare #EUXCT

?? The Recommendations Public Consultation period is extended! ?? New closing date: 31 March 2025, 12 PM CEST The public consultation for the EU-X-CT draft recommendations has been extended, giving you more time to share your feedback. If you haven’t had the chance to review the recommendations, now is the time! Your insights are essential to ensuring these guidelines support safe and equitable access to cross-border clinical trials in Europe. ?? Review the draft and submit your comments here:?https://lnkd.in/eG769Jrf Let’s work together to remove barriers and make clinical trials more accessible for all! #ClinicalTrials #CrossBorder #HealthcareInnovation #PublicConsultation #PatientAdvocacy

The European Parliament has launched a survey on?Rare diseases. The survey is open until 31 March 2025 and accessible in different European official languages. The contribution of patients/caregivers, healthcare professionals, researchers, healthcare providers, research institutes and other stakeholders is welcome. The purpose of this public consultation is to provide a basis for the forthcoming work of the Public Health Committee to gain a better understanding and detailed knowledge of the challenges faced by people affected by rare diseases and the views of people working with or involved in rare diseases. ?? ????????????, ???????????????? ?????? ???????????? ?????? ???????????? ?????? ???????? (?????????? ???????? ????????). ???? ???????? ?????????????? ?????? ???? ???????????????? ?????????????? ?????? ?????????????????? ???????????????????????? ???????? ?????? ?????????????????? ???????????????? ?????????????????? ?????? ????????????! ? https://lnkd.in/eHuHn64J Pirkko Lepola conect4children Segolene Gaillard Leticia Beleta i4KIDS I i4KIDS-EUROPE Hospital Sant Joan de Déu Barcelona EUPATI